Emergency medicine Australasia : EMA

Is homatropine 5% effective in reducing pain associated with corneal abrasion when compared with placebo? A randomized controlled trial.

PMID 21143399


To compare the change in visual analogue scale (VAS) pain ratings over 24 h following mechanical corneal abrasion between patients receiving sixth hourly drops of either 5% homatropine or placebo. A triple blind randomized controlled trial was conducted on a convenience sample of eligible consenting adults who were randomized to receive either sixth hourly 5% homatropine (active) or 0.5% hypromellose (placebo) eye drops. VAS pain ratings were performed at 0, 6, 12, 18 and 24 h whereas the study drug was instilled at 0, 6, 12 and 18 h. The primary outcome was attainment of a clinically significant reduction in pain on the VAS (>20 mm decrease) from enrolment to each time point. There were no significant differences in baseline variables or VAS pain ratings at any time point between those in the homatropine (n= 20) and placebo (n= 20) groups. The percentages of patients reporting a >20 mm VAS decrease at 12 h were 50% (95% CI -27.2-72.8) and 60% (95% CI -36.1-80.9) for the homatropine and placebo groups, respectively. We found no significant difference in pain score reductions between the two groups but some level of therapeutic benefit is not excluded.

Related Materials

Product #



Molecular Formula

Add to Cart

Homatropine hydrobromide, European Pharmacopoeia (EP) Reference Standard
C16H21NO3 · HBr